Scinai Immunotherapeutics (NASDAQ:SCNI) Announces Quarterly Earnings Results

Scinai Immunotherapeutics (NASDAQ:SCNI) released its quarterly earnings data on Wednesday. The company reported $0.94 earnings per share for the quarter, Zacks reports. The business had revenue of $0.49 million during the quarter.

Scinai Immunotherapeutics Stock Performance

Shares of SCNI stock opened at $0.33 on Friday. The business’s 50-day moving average price is $0.53 and its 200-day moving average price is $0.73. Scinai Immunotherapeutics has a 12 month low of $0.31 and a 12 month high of $3.48. The firm has a market capitalization of $1.29 million, a price-to-earnings ratio of -0.03 and a beta of 2.05. The company has a current ratio of 1.30, a quick ratio of 1.30 and a debt-to-equity ratio of 0.12.

Analysts Set New Price Targets

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Scinai Immunotherapeutics in a research note on Tuesday, April 21st. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, Scinai Immunotherapeutics has an average rating of “Sell”.

Institutional Trading of Scinai Immunotherapeutics

A hedge fund recently raised its stake in Scinai Immunotherapeutics stock. Citadel Advisors LLC grew its position in shares of Scinai Immunotherapeutics Ltd. Sponsored ADR (NASDAQ:SCNI) by 146.8% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 28,630 shares of the company’s stock after purchasing an additional 17,031 shares during the quarter. Citadel Advisors LLC owned approximately 0.90% of Scinai Immunotherapeutics worth $36,000 as of its most recent SEC filing. 58.41% of the stock is currently owned by institutional investors.

About Scinai Immunotherapeutics

Scinai Immunotherapeutics Inc is a clinical-stage biotechnology company dedicated to developing novel small-molecule therapies that enhance the immune system’s capacity to recognize and destroy cancer cells. The company’s research emphasizes checkpoint modulation and the discovery of compounds designed to work in concert with established immuno-oncology treatments across a range of solid tumors.

Scinai’s pipeline comprises preclinical and early-stage candidates, and the company relies on collaborations with academic institutions and contract research organizations to advance its discovery and development efforts.